<DOC>
	<DOCNO>NCT02052713</DOCNO>
	<brief_summary>The purpose study assess bioequivalence second generation dutasteride tamsulosin hydrochloride ( HCL ) combination capsule versus currently available commercial combination dutasteride 0.5 milligram ( mg ) tamsulosin HCL 0.4 mg capsule healthy adult male subject . Subjects study receive either single oral dose second generation dutasteride 0.5 mg tamsulosin 0.4 mg combination capsule single dose commercially available combination dutasteride 0.5 mg tamsulosin HCL 0.4 mg follow 28-day washout period fast state . The study enroll approximately 92 healthy adult male subject order complete approximately 76 evaluable subject . The total duration subject 's involvement study anticipate approximately 12 week .</brief_summary>
	<brief_title>Bioequivalence Study Second Generation Dutasteride Tamsulosin Hydrochloride ( HCL ) Combination Capsule Fasted State</brief_title>
	<detailed_description />
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Males 18 50 year age , inclusive . Weight range 55 95 kg ( inclusive ) body mass index ( BMI ) 18 30 kilogram/meter^2 ( kg/m^2 ) ( inclusive ) . Healthy subject define individual free clinically significant illness disease determine investigator base medical history , physical examination , vital sign , laboratory study , electrocardiogram ( ECGs ) . Single QT interval correct ( QTc ) &lt; 450 millisecond ( msec ) QTc &lt; 480 msec subject Bundle Branch Block , clinically relevant abnormal find screen ECG . Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) screening . Cytochrome P450 enzyme 2D6 ( CYP2D6 ) Extensive Metabolizers screen Willing able give write informed consent . Able swallow retain oral medication . Male subject female partner childbearing potential must agree use 1 contraception method . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatise ( ALP ) , bilirubin &lt; =1.5 x ULN ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . History postural hypotension , dizziness , poor hydration , vertigo , vasovagal reaction sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . History serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , interfere subject 's ability follow indication study procedure , interpretation study result obtain informed consent compliance study procedure opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor . History myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident prior Screening visit ; diabetes peptic ulcer disease uncontrolled medical management . History breast cancer clinical breast examination find suggestive malignancy , malignancy within past 5 year , except basal cell carcinoma skin . Subjects prior malignancy evidence disease least past 5 year eligible . Prior medical history evidence prostate cancer . Subjects suspicious ultrasound Digital Rectal Examination ( DRE ) negative biopsy within precede 6 month stable prostate specific antigen ( PSA ) eligible study . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Positive human immunodeficiency virus ( HIV ) test screening . Use prescription nonprescription drug . Strong Cytochrome P450 enzyme 3A4 ( CYP3A4 ) inhibitor ( e.g . ketoconazole ) and/or strong CYP2D6 inhibitor ( e.g . paroxetine ) usage throughout study . History sensitivity heparin heparininduced thrombocytopenia . History regular alcohol consumption exceed 21 drinks/week men ( 1 unit equivalent 8 gram alcohol : halfpint ( equivalent 240 millilitre [ mL ] ) beer , 1 glass ( equivalent 125 mL ) wine 1 ( equivalent 25 mL ) measure spirit ) within 6 month screen . Subjects must able willing abstain beverage foods contain alcohol 24 hour prior first dose study medication completion final PK sample period . A positive urine drug alcohol screen result screen Day 1 . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepine . Subjects must able willing stop use tobacco nicotine containing product 24 hour prior dose duration confinement . At discretion Investigator , light smoker ( smoke &lt; =10 cigarettes day ) would consider study inclusion . The subject receive investigational product participate research trial within 6 month 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication anytime study period , exposure 4 new chemical entity within 12 month prior first dose day . Previous donation blood blood product excess 500 mL within 90 day prior first dose investigational product subject agrees donate blood study . History presence allergy , intolerance , contraindication sensitivity alpha blocker ( e.g. , tamsulosin ) , 5 alpha reductase inhibitor ( e.g. , dutasteride ) drug therapeutic class , soya peanut , ingredient Combodart , history drug allergy ( include true sulfonamide allergy ) , opinion investigator , contraindicate participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>tamsulosin</keyword>
	<keyword>combination capsule dutasteride 0.5 mg tamsulosin HCL 0.4 mg</keyword>
	<keyword>dutasteride</keyword>
	<keyword>dutasteride tamsulosin combination</keyword>
	<keyword>healthy subject</keyword>
</DOC>